logo
Not alone: Beloved editor battling cancer humbled by R700k donations, some from strangers

Not alone: Beloved editor battling cancer humbled by R700k donations, some from strangers

News2427-04-2025

In three short months, Andrew Trench's life was turned upside down by the shocking news that he had stage four oesophageal cancer.
After his medical costs were declined by his insurer for a specific drug treatment, he resigned himself that he was going to die.
But the kindness of friends and strangers, who helped him raise R700 000 against a R3.5-million target, made him realise he might have a fighting chance.
It's not easy learning that you have a terminal disease. It's even more difficult when the news comes out of the blue, and when the cancer has already progressed to stage four.
This was Andrew Trench's reality in January this year. A few weeks prior, on New Year's Eve, the well-known news editor had just completed an epic open water, 12km swim and had never felt greater.
Fast forward a few weeks, and his world has completely changed.
"The days can be so different. You can be horribly ill on one day and not be able to get out of bed, and the next day you can feel something close to being a normal person," he told News24 this week.
"You really just have to roll with the punches, and today I feel not too bad."
The diagnosis completely upended his life. Before visiting his doctor after complaining about feeling ill, he was an entrepreneur building his own business, enjoying fitness and health, looking to retire in 10 years.
"You get this news out of the blue and it completely redefines what you do. So, just getting through each day becomes the complete centre of your universe."
He used to do all the cooking in his home. Now chopping a tomato takes some effort, and so there is a knock-on effect on the family as well.
'I basically accepted that I was going to die, but then…'
Andrew's survival chances could be greatly increased with a drug called Keytruda. It is, however, very expensive, and he was turned down by his insurer, as he didn't have the right product to activate coverage.
OPINION | My life and death got corporatised, but the kindness of South Africans may change the odds
Staring death in the face, like many in his position, he thought he didn't have much hope in raising the R3.5 million he needed over two years of treatment in a worst-case scenario.
He decided to launch a BackaBuddy campaign anyway, and a Facebook campaign called Andrew's Fighting Chance. On the first day, it raised R244 000.
"Up until the point where we launched the fundraiser, I basically accepted that I am going to die within a year at most, because without this treatment, the odds were not looking too good, and I couldn't see how we could raise enough money fast enough.
"But after the first week, we were on half a million, and that initial amount was enough for me to start the treatment three weeks ago. I went from a place of complete despair and acceptance about the hand that's been dealt to me, to a point that maybe there's a chance."
Scale of cancer matched by the help of strangers
What Andrew was not expecting was the scale at which so many people would offer to help, how many of them would be strangers, and just how many of those people have been affected by cancer.
"I've been completely blown away by that, myself and my wife. On the first day of trying to fundraise, my wife came from work and collapsed from tears. And this time not from grief or sadness, but overwhelmed by the generosity of people. It's been completely and utterly humbling.
"We've had about over 600 individual donations. I know a lot of people but I don't know 600 who would give me donations. It's also incredible how many people who are helping are absolute strangers. I've never met them and will never meet them."
One that stands out was another journalist in Sweden, who was moved by Andrew's story after reading about it on LinkedIn.
"He said, 'I don't know you, I'm also a journalist and I hope you get better, here's R5 000.' How does a stranger from another part of the world give you R5 000? It's mind-blowing.
In his view, around every second person who has been in touch with him has had their own cancer story to tell.
It's this, Andrew believes, that has made his story so relatable, sparking a resilience in a community of people who have all stared down their own fates.
"I actually had no idea that cancer was so prevalent. It's shocking how most people are being treated. It's almost become a battle for the middle class or the wealthy, because I don't know how, if you were poor in this country, you'd actually survive.
"The only option is to reach out to your community, but here in South Africa', you're in for a surprise, because people will help."
Ribbon Run, Swim Challenge and the bravery to tell your story
Andrew's community is now pushing full steam to helping him reach the enormous R3.5-million target, following the initial R710 000 raised.
There is still a way to go, but two events have been organised for him. The first is Andrew's Fighting Chance Swim Challenge. Based on the 12km swim he completed on New Year's Eve, he is challenging people to do the same swim. Some of the participants include Michelle Weber – a two-time open water Olympic swimmer.
Another involves Andrew's running club, called the Ribbon Run. Runners in his neighbourhood of Pinelands in Cape Town are given a yellow ribbon in exchange for a donation which they can drop off at his home as they run past. All the ribbons collected will be placed on a tree in his front garden. The first run started this Friday.
"That was the whole point of the campaign, rather than not just fade away, but it's an opportunity to make a difference in fighting this thing. So it's energised me, that this might be worth putting some sweat into because it could actually save your life."
Supplied
Andrew doesn't know what his future holds. The odds are still stacked against him and he still has a long way to go to raise the funds needed in the worst-case scenario.
He can only take one day at a time, but reflecting on his situation, he had this to share with other South Africans who may need some encouragement in the face of darkness: "When you are confronted by something like this, you must never for one instance think that you're on your own. That's very much what I felt in the beginning. But the realisation is that you're not on your own. You must be brave enough to stand up and tell your story, be humble enough to ask for help, and be smart enough to learn the lessons that you will from this.
"There's tons of hope as long as you throw yourself at the mercy of people who you ask for help, because they will, even if you think they won't."
- Andrew Trench is a veteran journalist who has been editor of News24, the Daily Dispatch, The Witness and The Times in his career. The links to Andrew's Fighting Chance fundraising campaign are here and here.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout

Yahoo

time2 days ago

  • Yahoo

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout

Shares of small-biotech MoonLake Immunotherapeutics MLTX rose 18% yesterday following a report issued by the Financial Times (FT), which stated that pharma giant Merck MRK is interested in acquiring the company. Per the article, Merck had submitted a non-binding offer for MoonLake earlier this year in a deal valued at more than $3 billion. Though this offer was rejected, the FT stated that the talks could be revived and other suitors may express interest in acquiring MLTX. Both Merck and MoonLake have declined to comment on the rumor. Swiss-based MoonLake Immunotherapeutics is a clinical-stage company developing its lead pipeline asset, sonelokimab, for the treatment of inflammatory diseases. The drug is a novel nanobody therapy being developed in late-stage studies for hidradenitis suppurativa (HS) and psoriatic arthritis (PsA) indications. Topline data from the HS study is expected around September 2025. MoonLake is also developing sonelokimab for other indications in dermatology and rheumatology, including palmo-plantar pustulosis (PPP) and axial spondyloarthritis (axSpA). Year to date, the stock has lost 10% compared with the industry's 4% decline. Image Source: Zacks Investment Research The idea behind the deal is clear — Merck aims to diversify its current revenue base, which has become highly dependent on Keytruda. In 2024, the company generated nearly 46% of its total revenues from the drug's sales. With concerns over Keytruda's potential loss of exclusivity (LOE) after 2028, MRK remains under pressure from the investor community to pursue deals for new drugs that could help reduce its dependence on a single product for growth. In the past year, Merck has been tapping Chinese biotechs for licensing deals. Toward the end of last year, the company struck multi-billion-dollar deals with Hansoh Pharma, LaNova Medicines and Hengrui Pharma. While the Hansoh deal added the investigational oral GLP-1 receptor agonist HS-10535 to Merck's pipeline, the LaNova deal added the experimental bispecific VEGF/PD-1 antibody LM-299. With the Hengrui Pharma deal, Merck acquired rights to an investigational oral small-molecule lipoprotein(a) inhibitor, HRS-5346. While broader macroeconomic concerns — including Trump-era tariffs and leadership shifts at the FDA — have weighed on deal-making in 2025, Big Pharma continues to pursue strategic assets in key growth areas. This week, Sanofi SNY announced a $9.5 billion acquisition of Blueprint Medicines to strengthen its immunology pipeline and reduce reliance on blockbuster drug Dupixent. Through this transaction, Sanofi intends to add Ayvakit — an inhibitor of KIT and PDGFRA proteins with growing commercial traction — and several early-stage pipeline assets focused on systemic mastocytosis (SM). Sanofi expects to close this deal in the third quarter of 2025. In parallel, Bristol Myers Squibb BMY signed a co-development and commercialization agreement with BioNTech for BNT327, an investigational bispecific antibody targeting PD-L1 and VEGF. The deal gives Bristol Myers access to a promising oncology candidate across multiple tumor types, aligning with its strategy to offset revenue declines from legacy brands. These transactions highlight the industry's ongoing interest in targeted immunology and oncology platforms — the same areas MoonLake's sonelokimab is exploring. Merck's rumored pursuit of MoonLake fits this trend, signaling that small biotechs with promising assets remain top M&A targets for Big Pharma. MoonLake Immunotherapeutics price | MoonLake Immunotherapeutics Quote MoonLake currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report MoonLake Immunotherapeutics (MLTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research

Analyst Says Merck (MRK) is ‘Really Cheap' But Warns About Potential ‘Bad News'
Analyst Says Merck (MRK) is ‘Really Cheap' But Warns About Potential ‘Bad News'

Yahoo

time2 days ago

  • Yahoo

Analyst Says Merck (MRK) is ‘Really Cheap' But Warns About Potential ‘Bad News'

Bill Stone, Glenview Trust Company chief investment officer, mentioned his bullish take on Merck (NYSE:MRK) during a recent program on CNBC and explained the potential risks and rewards tied to the stock: 'There's good news and bad news. The good news is they own Keytruda, which has been just a phenomenal success in treating many different types of cancer. The bad news is the patent comes off in 2028, and it will be somewhere approaching maybe 50% of the revenues by that point. So you really have to be a believer that they can restock the cabinet, that they could come up with other versions of Keytruda or versions of it that won't go to generic completely. Stock is really cheap, at like nine times earnings with a nice dividend. So I think you're getting paid to kind of take on that risk.' Photo by Kaleidico on Unsplash Artisan Value Fund stated the following regarding Merck & Co., Inc. (NYSE:MRK) in its Q1 2025 investor letter: 'Shares of Merck & Co., Inc. (NYSE:MRK), a health care solutions company, were down 9%. Operating results have been solid, with Q4 earnings beating expectations, but investors were more focused on the continued weak demand in China for Gardasil, a vaccine for human papillomavirus (HPV), and the company's decision to pause vaccine shipments through at least mid-2025 to pare inventories. Though recent Gardasil setbacks have weighed on sentiment, the overarching issue for shareholders remains the success of Merck's late-stage pipeline to replace sales that will be lost when blockbuster oncology drug Keytruda (50% of Q4sales) comes off patent in 2028. As shares sell cheaply at just 10X earnings, Merck seems to be getting little credit from investors for the 60+ programs it has in clinical development, despite having several solid and large new product opportunities. Additionally, the company's strong balance sheet and robust free cash flow provide it multiple options for future partnerships and acquisitions, besides return of capital to shareholders via dividends and share repurchases.' READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.

Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

Business Wire

time2 days ago

  • Business Wire

Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)--Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ('Alvotech'), and Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as 'Dr. Reddy's'), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets. Keytruda® (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were US$29.5 billion [1]. The collaboration combines Dr. Reddy's and Alvotech's proven capabilities in biosimilars, thereby, speeding up the development process and extending the global reach for this biosimilar candidate. Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain exceptions, each party will have the right to commercialize the product globally. 'We are very pleased to enter into this collaboration for pembrolizumab with Dr. Reddy's. This agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets. It further enables us to increase the availability of cost-effective, critical biologic medications to patients world-wide,' said Róbert Wessman, chairman and CEO of Alvotech. "We are happy to collaborate with Alvotech for the pembrolizumab biosimilar. This demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide. Additionally, oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology,' said Erez Israeli, CEO of Dr. Reddy's. Use of trademarks Keytruda® is a registered trademark of Merck Sharp & Dohme Corp. Sources [1] About Alvotech Alvotech is a biotech company, founded by Róbert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy's (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit None of the information on the Alvotech website shall be deemed part of this press release. For more information visit Alvotech's investor portal, and website or follow Alvotech on social media on LinkedIn, Facebook, Instagram, and YouTube. Alvotech Forward Looking Statements Certain statements in this communication may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech's expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, and market launches. In some cases, you can identify forward-looking statements by terminology such as 'may', 'should', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential', 'aim' or 'continue', or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability to develop or co-develop future products, including the proposed biosimilar to Keytruda®; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (5) Alvotech's estimates of expenses and profitability; (6) Alvotech's ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (8) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (10) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (11) the ability of Alvotech's partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (12) Alvotech's ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (13) the success of Alvotech's current and future collaborations, joint ventures, partnerships or licensing arrangements; (14) Alvotech's ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (15) Alvotech's ability to manufacture sufficient commercial supply of its approved products; (16) the outcome of ongoing and future litigation regarding Alvotech's products and product candidates; (17) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, conflicts in Ukraine, the Middle East and other global geopolitical tension, on the Company's business, financial position, strategy and anticipated milestones; and (18) other risks and uncertainties set forth in the sections entitled 'Risk Factors' and 'Cautionary Note Regarding Forward-Looking Statements' in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication. About Dr. Reddy's Laboratories Ltd: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil, and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. Over the last 25 years, our Biologics team has developed into a fully integrated organization with robust capabilities in the development, manufacture and commercialization of a range of biosimilar products in oncology and immunology. We have a current portfolio of six commercial products marketed in India, with some products marketed in more than 30 other countries. In addition, we have several products in the pipeline in oncology and auto-immune diseases in various stages of development for global launches across developed as well as emerging markets. We are also ramping up manufacturing capacity to support our global expansion plans. In 2024, we launched our first biosimilar in the United Kingdom, Versavo® (biosimilar bevacizumab). This follows our launch of pegfilgrastim in the U.S and Europe through our partner. Our biosimilars business has a key role to play in driving both near-term and long-term growth. For more information, log on to: Dr. Reddy's Disclaimer This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2024. The company assumes no obligation to update any information contained herein. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product's label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store